leflunomide has been researched along with Berger Disease in 18 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the therapeutic effects and safety of a combination therapy of leflunomide (LEF) and prednisone for the treatment of immunoglobulin A (IgA) nephropathy manifesting with nephrotic syndrome." | 9.14 | Comparison of the therapeutic effects of leflunomide and mycophenolate mofetil in the treatment of immunoglobulin A nephropathy manifesting with nephrotic syndrome. ( Li, DM; Liu, XW; Sun, SR; Xu, GS, 2010) |
| "To evaluate the therapeutic effects and safety of a combination therapy of leflunomide (LEF) and prednisone for the treatment of immunoglobulin A (IgA) nephropathy manifesting with nephrotic syndrome." | 5.14 | Comparison of the therapeutic effects of leflunomide and mycophenolate mofetil in the treatment of immunoglobulin A nephropathy manifesting with nephrotic syndrome. ( Li, DM; Liu, XW; Sun, SR; Xu, GS, 2010) |
| "Leflunomide therapy significantly improved proteinuria (Plt;0." | 5.12 | [Effects of leflunomide combined with hormone therapy for refractory IgA nephropathy]. ( Liu, ZR; Rong, L, 2007) |
| "Leflunomide can decrease the deposit of immunocomplex, down regulate the expression of TGF-beta1, MCP-1 in kidney, diminish local inflammatory reaction, relieve hyperplasia of mesangial matrix, related the process of nephrotic fibrosis, and protect renal function." | 3.74 | [Study on protective effects and its mechanism of leflunomide on renal tissue in rat IgA nephropathy model]. ( Liu, X; Lou, TQ; Peng, H; Tang, H; Tang, Y; Wang, C, 2008) |
| " We administered tofacitinib combined with leflunomide to a 38-year-old female patient who presented with PsA and IgA nephropathy." | 2.82 | Tofacitinib combined with leflunomide for treatment of psoriatic arthritis with IgA nephropathy: a case report with literature review. ( Ci, X; Du, X; Li, L; Lu, X; Luo, M; Wu, L; Xue, H, 2022) |
| "The treatment with Valsartan combined with Clopidogrel and Leflunomide can reduce the urinary proteins loss and renal function deterioration for IgA nephropathy patients and cause minimal adverse reactions." | 2.80 | Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy. ( Chen, F; Cheng, G; Fang, Y; Guo, Y; Li, H; Liu, D; Liu, F; Liu, L; Liu, Z; Margetts, P; Tang, L; Zhao, Z, 2015) |
| "Sixty IgA nephropathy patients were divided into two groups at random." | 2.72 | Randomised controlled trial of leflunomide in the treatment of immunoglobulin A nephropathy. ( Chen, Z; Liu, X; Lou, T; Shi, C; Tang, H; Wang, C; Yin, P; Yu, X, 2006) |
| "In patients with IgA nephropathy and proteinuria > 1 g/day, steroid therapy given for generally two to four months with a tapering course probably prevents the progression to ESKD compared to placebo or standard care (8 studies; 741 participants: RR 0." | 2.66 | Immunosuppressive agents for treating IgA nephropathy. ( Craig, JC; Molony, DA; Natale, P; Palmer, SC; Ruospo, M; Saglimbene, VM; Samuels, JA; Schena, FP; Strippoli, GF; Vecchio, M, 2020) |
| "Leflunomide (LEF) is an immunosuppressive drug which may reduce deposition of glomerular autoantibodies and immune complexes." | 2.61 | Efficacy and safety of leflunomide in IgA nephropathy: a systematic review and meta-analysis. ( Feng, S; He, Z; Xu, S; Yi, J, 2019) |
| "To investigate the efficacy and potential molecular mechanism of Huangkui capsule in combination with leflunomide (HKL) for the treatment of immunoglobulin A nephropathy (IgAN)." | 1.62 | Huangkui Capsule in Combination with Leflunomide Improves Immunoglobulin A Nephropathy by Inhibiting the TGF-β1/Smad3 Signaling Pathway. ( Li, Y; Pei, S, 2021) |
| "Primary IgA nephropathy (IgAN) and HSPN share common features; thus, the Oxford classification of IgAN might be useful in predicting the long-term outcomes of HSPN." | 1.48 | Value of the Oxford classification of IgA nephropathy in children with Henoch-Schönlein purpura nephritis. ( Ding, J; Li, Y; Su, B; Wang, F; Wang, S; Xiao, H; Xu, K; Zhang, L; Zhong, X, 2018) |
| "Biopsy-proved primary IgA nephropathy patients with an estimated glomerular filtration rate ≥ 30 ml/min/1." | 1.46 | Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy. ( Cao, L; Che, X; Fang, W; Gu, L; Min, L; Mou, S; Ni, Z; Qian, J; Wang, L; Wang, Q; Yu, Z; Yuan, J; Zhang, M; Zhou, W; Zhu, M, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (16.67) | 29.6817 |
| 2010's | 9 (50.00) | 24.3611 |
| 2020's | 6 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Y | 3 |
| Xiong, Y | 1 |
| Huang, T | 1 |
| Liu, X | 3 |
| Xu, G | 1 |
| Pei, S | 1 |
| Xue, H | 1 |
| Ci, X | 1 |
| Luo, M | 1 |
| Wu, L | 1 |
| Du, X | 1 |
| Li, L | 1 |
| Lu, X | 1 |
| Yi, J | 1 |
| He, Z | 1 |
| Xu, S | 1 |
| Feng, S | 1 |
| Natale, P | 1 |
| Palmer, SC | 1 |
| Ruospo, M | 1 |
| Saglimbene, VM | 1 |
| Craig, JC | 1 |
| Vecchio, M | 1 |
| Samuels, JA | 1 |
| Molony, DA | 1 |
| Schena, FP | 1 |
| Strippoli, GF | 1 |
| Ni, J | 1 |
| Zhu, C | 1 |
| Ni, X | 1 |
| Yin, J | 1 |
| Ni, Z | 2 |
| Zhang, Z | 1 |
| Yu, Z | 2 |
| Lu, F | 1 |
| Mei, C | 1 |
| Ding, X | 1 |
| Yuan, W | 1 |
| Zhang, W | 1 |
| Jiang, G | 1 |
| Sun, M | 1 |
| He, L | 1 |
| Deng, Y | 1 |
| Pang, H | 1 |
| Qian, J | 2 |
| Min, L | 1 |
| Wang, Q | 1 |
| Cao, L | 1 |
| Zhou, W | 1 |
| Yuan, J | 1 |
| Zhang, M | 1 |
| Che, X | 1 |
| Mou, S | 1 |
| Fang, W | 1 |
| Gu, L | 1 |
| Zhu, M | 1 |
| Wang, L | 2 |
| Xu, K | 1 |
| Zhang, L | 1 |
| Ding, J | 1 |
| Wang, S | 1 |
| Su, B | 1 |
| Xiao, H | 1 |
| Wang, F | 1 |
| Zhong, X | 2 |
| Chen, S | 1 |
| Yin, Q | 1 |
| Ren, S | 1 |
| Wang, W | 1 |
| Li, G | 1 |
| Cheng, G | 1 |
| Liu, D | 1 |
| Margetts, P | 1 |
| Liu, L | 1 |
| Zhao, Z | 1 |
| Liu, Z | 1 |
| Tang, L | 1 |
| Fang, Y | 1 |
| Li, H | 1 |
| Guo, Y | 1 |
| Chen, F | 1 |
| Liu, F | 1 |
| Wu, J | 2 |
| Duan, SW | 1 |
| Sun, XF | 1 |
| Li, WG | 1 |
| Wang, YP | 1 |
| Liu, WH | 1 |
| Zhang, JR | 1 |
| Lun, LD | 1 |
| Li, XM | 1 |
| Zhou, CH | 1 |
| Li, JJ | 1 |
| Liu, SW | 1 |
| Xie, YS | 1 |
| Cai, GY | 1 |
| Ma, L | 1 |
| Huang, W | 1 |
| Wu, H | 1 |
| Jia, Q | 1 |
| Chen, XM | 1 |
| Chen, YZ | 1 |
| Zhao, XZ | 1 |
| Mei, CL | 1 |
| Liu, XW | 1 |
| Li, DM | 1 |
| Xu, GS | 1 |
| Sun, SR | 1 |
| Sanders, JS | 1 |
| Riezebos-Brilman, A | 1 |
| Homan van der Heide, JJ | 1 |
| Lou, T | 1 |
| Wang, C | 2 |
| Chen, Z | 1 |
| Shi, C | 1 |
| Tang, H | 2 |
| Yin, P | 1 |
| Yu, X | 1 |
| Rong, L | 1 |
| Liu, ZR | 1 |
| Tang, Y | 1 |
| Lou, TQ | 1 |
| Peng, H | 1 |
4 reviews available for leflunomide and Berger Disease
| Article | Year |
|---|---|
Tofacitinib combined with leflunomide for treatment of psoriatic arthritis with IgA nephropathy: a case report with literature review.
Topics: Adult; Arthritis, Psoriatic; Female; Glomerulonephritis, IGA; Humans; Leflunomide; Piperidines; Psor | 2022 |
Efficacy and safety of leflunomide in IgA nephropathy: a systematic review and meta-analysis.
Topics: Glomerulonephritis, IGA; Humans; Immunosuppressive Agents; Leflunomide; Treatment Outcome | 2019 |
Immunosuppressive agents for treating IgA nephropathy.
Topics: Adult; Calcineurin Inhibitors; Cause of Death; Child; Confidence Intervals; Creatinine; Drug Adminis | 2020 |
Combination regimen of leflunomide plus methylprednisolone in a female patient with reactive arthritis and concomitant IgA nephropathy.
Topics: Adolescent; Adult; Arthritis, Reactive; Drug Combinations; Female; Glomerulonephritis, IGA; Humans; | 2010 |
6 trials available for leflunomide and Berger Disease
| Article | Year |
|---|---|
Leflunomide plus low-dose prednisone in patients with progressive IgA nephropathy: a multicenter, prospective, randomized, open-labeled, and controlled trial.
Topics: Adult; China; Creatinine; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glomerulone | 2021 |
Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Biomarkers; China; Clopidogrel; Creatinine; Disease | 2015 |
Efficacy of Leflunomide, Telmisartan, and Clopidogrel for Immunoglobulin A Nephropathy: A Randomized Controlled Trial.
Topics: Adolescent; Adult; Benzimidazoles; Benzoates; Blood Pressure; China; Clopidogrel; Creatinine; Female | 2016 |
Comparison of the therapeutic effects of leflunomide and mycophenolate mofetil in the treatment of immunoglobulin A nephropathy manifesting with nephrotic syndrome.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Drug Therapy, Combination; Female; Glomerulonephritis, | 2010 |
Randomised controlled trial of leflunomide in the treatment of immunoglobulin A nephropathy.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Angiotensin-Converting Enzyme Inhibitors; Female; Fosinop | 2006 |
[Effects of leflunomide combined with hormone therapy for refractory IgA nephropathy].
Topics: Adult; Drug Resistance; Drug Therapy, Combination; Female; Glomerulonephritis, IGA; Hormones; Humans | 2007 |
8 other studies available for leflunomide and Berger Disease
| Article | Year |
|---|---|
Clinical efficacy and safety of full-dose versus half-dose corticosteroids plus leflunomide for IgA nephropathy.
Topics: Adrenal Cortex Hormones; Adult; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies | 2021 |
Huangkui Capsule in Combination with Leflunomide Improves Immunoglobulin A Nephropathy by Inhibiting the TGF-β1/Smad3 Signaling Pathway.
Topics: Animals; Drugs, Chinese Herbal; Glomerulonephritis, IGA; Humans; Kidney; Leflunomide; Rats; Signal T | 2021 |
IgA nephropathy associated with thalassemia: a case report.
Topics: Adult; alpha-Thalassemia; Angiotensin Receptor Antagonists; Female; Folic Acid; Glomerulonephritis, | 2020 |
Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy.
Topics: Adrenal Cortex Hormones; Adult; Biomarkers; Blood Pressure; Disease Progression; Drug Therapy, Combi | 2017 |
Value of the Oxford classification of IgA nephropathy in children with Henoch-Schönlein purpura nephritis.
Topics: Adolescent; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Atrophy; Biopsy; Child; Child, Pr | 2018 |
A comparison of the effectiveness of cyclophosphamide, leflunomide, corticosteroids, or conservative management alone in patients with IgA nephropathy: a retrospective observational study.
Topics: Adrenal Cortex Hormones; Adult; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Convertin | 2018 |
Progressive multifocal leuko-encephalopathy after ABO-incompatible kidney transplantation.
Topics: ABO Blood-Group System; Blood Group Incompatibility; Glomerulonephritis, IGA; Humans; Immunosuppress | 2012 |
[Study on protective effects and its mechanism of leflunomide on renal tissue in rat IgA nephropathy model].
Topics: Animals; Chemokine CCL2; Disease Models, Animal; Fibrosis; Glomerulonephritis, IGA; Isoxazoles; Kidn | 2008 |